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AN INSTITUTIONAL PERSPECTIVE ON THE EFFICACY OF DONOR LEUKO-
CYTE INFUSIONS FOR PATIENTS WITH POST-TRANSPLANT RELAPSE
Myers, L.1, Burmeister, J.1, Mater, E.1, Murray, S.1, Curtin, P.T.2,
Gajewski, J.L.1, Hayes-Lattin, B.1, Kovacsovics, T.1, Leis, J.F.3,
Meyers, G.1, Slater, S.1, Maziarz, R.T.1 1Oregon Health and Science
University, Portland, OR; 2University of California San Diego, San
Diego, CA; 3Mayo Clinic Hospital, Scottsdale, AZ
Patients with post-allogeneic HSCTdisease relapse can be treated
with salvage chemotherapy but are also candidates for immune sup-
pression withdrawal and/or donor lymphocyte infusion (DLI).
A total of 237 adult patients experienced relapse of disease post-al-
logeneic transplant at our institution between 1995 and 2010. A ret-
rospective institutional analysis was performed on the 52 patients
who received DLI in that timeframe. The DLI product infusion
doses ranged from 0.07 to 4.0 x 108 CD3+ cells.
CML patients had the most favorable DLI response rates with
78% (n 5 7) in remission at 3 years. Patients with relapsed AML/
MDS and lymphoid malignancies fared worse with 36% and 21%
OS at 3 years respectively. OS was superior in patients in CR prior
to DLI (45%) compared to those with active disease (5%) and for pa-
tients under the age of 50 (32% vs 21%). Three year OS was ob-
served of 5% for patients who relapsed prior to day +100, 29% for
relapse between day +100 and 1 year, and 59% for relapse after 1
year. Patients who developed GvHD prior to relapse had a 3 year
OS of 35% vs 9% in patients without GvHD. Patients with post-
DLI GvHD had a 39%OS vs 11% for patients without GvHD after
DLI. No difference in post-DLI survival was noted with regards to
pre-transplant disease status, cell dose or transplant conditioning.
CML patients respond well to DLI however in the TKI era, trans-
plants for these patients are reserved for patients with TKI-resistant
disease. In other patients, immune suppression withdrawal and DLI
have limited efficacy for those who do not achieveCR post-relapse or
who relapse within 3 months of transplant. These patients are in
need of alternative treatment strategies.394
PRECONDITIONING WITH RAPAMYCIN AND CTLA4-Ig IN DOGS GIVEN
DONOR ANTIGEN AND 1Gy TOTAL BODY IRRADIATION (TBI) BEFORE
DOG-LEUKOCYTE-ANTIGEN (DLA)-IDENTICAL MARROW TRANSPLAN-
TATION FAILED TO ASSURE SUSTAINED ENGRAFTMENT
Wang, Z.1,2, Sorror, M.L.1,2, McCune, J.S.1,3, Butts, T.1,
Graves, S.G.1,2, Storb, R.1,2 1Fred Hutchinson Cancer Research Center,
Seattle, WA; 2University of Washington, Seattle, WA; 3University of
Washington, Seattle, WA
Stable engraftment of allogeneic, DLA-identical marrow can be
achieved by conditioning dogs with a nonmyeloablative dose of 2
Gy TBI followed by a brief course of postgrafting immunosuppres-
sion with cyclosporine (CSP) and mycophenolate mofetil (MMF).
However, when TBI dose was reduced to 1 Gy, CSP/MMF failed to
control host-versus-graft (HVG) reactions, and grafts were uniformly
rejected. CTLA4-Ig blocks T-cell costimulation through the
B7:CD28 signaling pathway and induces T cell anergy. We used
CTLA4-Ig concurrently with infusion of donor peripheral blood
mononuclear cells (PMBC) to blunt activated recipient T cells before
transplantation (Storb et al., Blood 94, p2523-2529, 1999). The regi-
men was effective in establishing stable mixed chimerism in67% of
the animals. Rapamycin mediates immunosuppression by inhibiting
both cytokine driven pathways and costimulatory signaling, and has
been reported to act in synergy with CTLA4-Ig for tolerance induc-
tion in solid organ transplantation. In the current study we asked
weather adding rapamycin to CTLA4-Ig before transplantation
would improveour earlier results and further aid in sustaining engraft-
ment. Accordingly, six recipient dogs were given CTLA4-Ig on days
-7 to -1 and rapamycin on days -6 to -2, with concurrent intravenous
administration of 10^6 (n5 2) or 10 x 10^6 (n5 4) PBMC from their
respective DLA-identical donors from days -7 to -1 before 1Gy TBI,
and CSP/MMF after marrow transplantation. The regimen was well
tolerated and all 6 dogs showed initial allogeneic engraftment. Only
one dog showed persistent mixed chimerism for more than 34 weeks
while 5 dogs rejected their allografts between 8 to 12 weeks followed
by autologous marrow recovery, a timing that was comparable to thatin control dogs. These findings illustrate the difficulty to achieve uni-
form sustained engraftment in DLA-identical dogs using pharmaco-
logical immunosuppression in combination with 1 Gy TBI.395
EVALUATION OF HCT-CI COMORBIDITY SCORES AND ALLOGENEIC
TRANSPLANT OUTCOME OF YOUNG ADULTS AFTER MYELOABLATIVE
CONDITIONING WITH FLUDARABINE AND BUSULFAN +/- TBI MALIG-
NANCIES
Slaby, J.1, Williamson, T.3, Chaudhry, A.M.1, Larratt, L.2,
Turner, R.A.2, Bahlis, N.J.1, Brown, C.B.1, Daly, A.1, Duggan, P.1,
Geddes, M.1, Quinlan, D.1, Savoie, M.L.1, Shafey, M.1, Storek, J.1,
Yue, P.1, Zacarias, N.1, Stewart, D.A.1, Russell, J.A.1, Russell, J.1 1Foot-
hills Medical Center and Tom Baker Cance Centre, Calgary, AB, Canada;
2Cross Cancer Institute, Edmonton, AB, Canada; 3Queen’s University,
Kingston, ON, Canada
We have previously reported an association between HCT-CI
scores 1 and more and increased TRM in allogeneic patients older
than 50 years. Now, we have analyzed HST-CI in 411 consecutive
younger patients with hematologic malignancy transplanted be-
tween 1999 and 2008.
Two hundred and thirty four patients had low-risk disease (ALCR
1 or 2, CMLCP), all others were considered high-risk. The myeloa-
blative regimen included fludarabine 250mg/m2 and intravenous bu-
sulfan 12.8mg/kg, 203 patients (49.4%) received additional TBI
(400cGy). CsA, MTX and Thymoglobulin (4.5mg/kg) were given
for GVHD prophylaxis. Donors were matched siblings in 208 cases
(50.6%); bone marrow, peripheral and umbilical blood were used in
73 (17.8%), 327 (79.5%) and 11 (2.7%) patients, respectively. Me-
dian age was 40 years (range 16-50) and median follow-up was 38
months (1-148 mo).
HCT-CI scoreswere0 in287 (70%), 1 in68 (16.5%),2 in27 (6.5%),
3 in22 (5.3%) and4 in7 (1.7%)patients.TRMofpatientswith score 0,
1, 2, or 3+was 13%, 12%, 33%and10%at1 year (p50.022) and14%,
15%, 33% and 14% at 3 years (p5 0.074), respectively.
Multivariate analysis only demonstrated an association of TRM
with HCT-CI score 2 (SHR 5 2.75; 95%CI: 1.27-5.98; p 5 0.01).
Three other factors were also significant: CMV status (SHR 5
2.02; 95%CI 1.1-3.71; p 5 0.024), alternative donor (SHR 5 1.95;
95%CI 1.17-3.25; p 5 0.010) and age (SHR 5 1.03 per year; 95%
CI 1.0-1.07; p 5 0.042).
Conclusions:
1. In contrast to older patients, the TRM of the combined group of
patients given a score of 1 and more was no different from those
with a score of 0.
2. Patients with score of 2 had significantly higher TRM.
3. Scores of 3 and 4 mostly represented previous malignancies and
pulmonary disease and did not seem to influence TRM in these
patients.
4. Increasing HCT-CI scores did not accurately reflect increasing
TRM in young patients treated with this regimen.396
PLATELET REFRACTORINESS IS ASSOCIATED WITH DELAYED PLATELET
ENGRAFTMENT AND INCREASED GRAFT VERSUS HOST DISEASE FOL-
LOWING PERIPHERAL BLOOD OR BONE MARROW DERIVED STEM
CELL TRANSPLANTATION
Gandhi, M.J., Schneider, B.A., Jenkins, S., Hogan, W.J., Litzow, M.R.,
Gastineau, D.A., Stubbs, J.R., Patnaik,M.S.Mayo Clinic, Rochester,MN
Background: Platelets (PLT) play a role in innate and adaptive im-
munity and possess pro-inflammatory, as well as pro-thrombotic
properties. PLT transfusion is associated with transfusion immuno-
modulation, resulting in alteration of the recipients’ immune func-
tion. Multiple PLT transfusions may result in alloimmunization
leading to refractoriness and greater transfusion requirements.
PLT refractoriness is relatively more common in patients undergo-
ing stem cell transplantation (SCT) for hematologic malignancies.
We analyzed the clinical outcomes in SCT patients with PLT
refractoriness.
